Do analysts rate MYNZ or TPCS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mainz Biomed 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Techprecision 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate XTIA or MYNZ?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score XTI Aerospace 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 Mainz Biomed 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Do analysts recommend SYPR or MYNZ?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sypris Solutions 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Mainz Biomed 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Do analysts recommend ZENA or MYNZ?

ZenaTech presently has a consensus price target of $4.50, indicating a potential upside of 167.86%. Given ZenaTech's stronger consensus rating and higher possible upside, equities research analysts plainly believe ZenaTech is more favorable than Mainz Biomed. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ZenaTech 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Mainz Biomed 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Is ZENA or MYNZ more profitable?

Mainz Biomed has a net margin of 0.00% compared to ZenaTech's net margin of -332.51%. Company Net Margins Return on Equity Return on Assets ZenaTech -332.51% N/A -78.90% Mainz Biomed N/A N/A N/A

Do analysts recommend MYNZ or VTSI?

VirTra has a consensus target price of $5.00, suggesting a potential upside of 61.81%. Given VirTra's stronger consensus rating and higher possible upside, analysts plainly believe VirTra is more favorable than Mainz Biomed. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Mainz Biomed 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 VirTra 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable earnings and valuation, MYNZ or VTSI?

VirTra has higher revenue and earnings than Mainz Biomed. VirTra is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Mainz Biomed $659.94K 20.87 -$21.65M -$65.60 N/A VirTra $22.40M 1.56 $260K -$0.26 N/A

Mainz Biomed (MYNZ) Competitors

$1.52 -0.08 (-5.00%)

As of 09/3/2026

Compare

MYNZ vs. TPCS, XTIA, SYPR, ZENA, and VTSI

Should you buy Mainz Biomed stock or one of its competitors? Mainz Biomed's main competitors and comparable companies include Techprecision (TPCS), XTI Aerospace (XTIA), Sypris Solutions (SYPR), ZenaTech (ZENA), and VirTra (VTSI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "aerospace & defense" industry.

How does Mainz Biomed compare to Techprecision?

Mainz Biomed (NASDAQ:MYNZ) and Techprecision (NASDAQ:TPCS) are both small-cap industrials companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, institutional ownership, analyst recommendations, risk, profitability and earnings.

15.5% of Techprecision shares are held by institutional investors. 18.2% of Mainz Biomed shares are held by company insiders. Comparatively, 15.3% of Techprecision shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Techprecision had 3 more articles in the media than Mainz Biomed. MarketBeat recorded 3 mentions for Techprecision and 0 mentions for Mainz Biomed. Techprecision's average media sentiment score of 1.07 beat Mainz Biomed's score of 0.00 indicating that Techprecision is being referred to more favorably in the news media.

Company	Overall Sentiment
Mainz Biomed	Neutral
Techprecision	Positive

Mainz Biomed has a beta of 0.31, indicating that its share price is 69% less volatile than the broader market. Comparatively, Techprecision has a beta of 0.41, indicating that its share price is 59% less volatile than the broader market.

Techprecision has higher revenue and earnings than Mainz Biomed. Techprecision is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mainz Biomed	$659.94K	20.87	-$21.65M	-$65.60	N/A
Techprecision	$31.64M	1.85	-$1.66M	-$0.13	N/A

Mainz Biomed has a net margin of 0.00% compared to Techprecision's net margin of -3.66%. Mainz Biomed's return on equity of 0.00% beat Techprecision's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mainz Biomed	N/A	N/A	N/A
Techprecision	-3.66%	-15.07%	-3.75%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mainz Biomed	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Techprecision	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Mainz Biomed and Techprecision tied by winning 7 of the 14 factors compared between the two stocks.

How does Mainz Biomed compare to XTI Aerospace?

XTI Aerospace (NASDAQ:XTIA) and Mainz Biomed (NASDAQ:MYNZ) are both small-cap industrials companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, media sentiment, risk, valuation, dividends and earnings.

11.7% of XTI Aerospace shares are held by institutional investors. 7.4% of XTI Aerospace shares are held by company insiders. Comparatively, 18.2% of Mainz Biomed shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, XTI Aerospace had 28 more articles in the media than Mainz Biomed. MarketBeat recorded 28 mentions for XTI Aerospace and 0 mentions for Mainz Biomed. Mainz Biomed's average media sentiment score of 0.00 beat XTI Aerospace's score of -0.17 indicating that Mainz Biomed is being referred to more favorably in the news media.

Company	Overall Sentiment
XTI Aerospace	Neutral
Mainz Biomed	Neutral

Mainz Biomed has a net margin of 0.00% compared to XTI Aerospace's net margin of -171.13%. Mainz Biomed's return on equity of 0.00% beat XTI Aerospace's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
XTI Aerospace	-171.13%	-2,044.78%	-105.02%
Mainz Biomed	N/A	N/A	N/A

Mainz Biomed has lower revenue, but higher earnings than XTI Aerospace. XTI Aerospace is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XTI Aerospace	$22.49M	1.81	-$68.76M	-$5.20	N/A
Mainz Biomed	$659.94K	20.87	-$21.65M	-$65.60	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XTI Aerospace	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
Mainz Biomed	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

XTI Aerospace has a beta of 4.79, suggesting that its stock price is 379% more volatile than the broader market. Comparatively, Mainz Biomed has a beta of 0.31, suggesting that its stock price is 69% less volatile than the broader market.

Summary

Mainz Biomed beats XTI Aerospace on 8 of the 15 factors compared between the two stocks.

How does Mainz Biomed compare to Sypris Solutions?

Sypris Solutions (NASDAQ:SYPR) and Mainz Biomed (NASDAQ:MYNZ) are both small-cap industrials companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, institutional ownership, risk, media sentiment, profitability, analyst recommendations and earnings.

Mainz Biomed has a net margin of 0.00% compared to Sypris Solutions' net margin of -9.23%. Mainz Biomed's return on equity of 0.00% beat Sypris Solutions' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sypris Solutions	-9.23%	-67.14%	-9.87%
Mainz Biomed	N/A	N/A	N/A

44.7% of Sypris Solutions shares are owned by institutional investors. 47.9% of Sypris Solutions shares are owned by insiders. Comparatively, 18.2% of Mainz Biomed shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Sypris Solutions has a beta of 0.88, suggesting that its share price is 12% less volatile than the broader market. Comparatively, Mainz Biomed has a beta of 0.31, suggesting that its share price is 69% less volatile than the broader market.

Sypris Solutions has higher revenue and earnings than Mainz Biomed. Sypris Solutions is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sypris Solutions	$119.89M	0.36	-$6.34M	-$0.47	N/A
Mainz Biomed	$659.94K	20.87	-$21.65M	-$65.60	N/A

In the previous week, Sypris Solutions had 1 more articles in the media than Mainz Biomed. MarketBeat recorded 1 mentions for Sypris Solutions and 0 mentions for Mainz Biomed. Sypris Solutions' average media sentiment score of 1.90 beat Mainz Biomed's score of 0.00 indicating that Sypris Solutions is being referred to more favorably in the media.

Company	Overall Sentiment
Sypris Solutions	Very Positive
Mainz Biomed	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sypris Solutions	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Mainz Biomed	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Summary

Sypris Solutions beats Mainz Biomed on 8 of the 14 factors compared between the two stocks.

How does Mainz Biomed compare to ZenaTech?

ZenaTech (NASDAQ:ZENA) and Mainz Biomed (NASDAQ:MYNZ) are both small-cap industrials companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, risk, institutional ownership, profitability, analyst recommendations and dividends.

Mainz Biomed has a net margin of 0.00% compared to ZenaTech's net margin of -332.51%.

Company	Net Margins	Return on Equity	Return on Assets
ZenaTech	-332.51%	N/A	-78.90%
Mainz Biomed	N/A	N/A	N/A

ZenaTech has a beta of 7.21, indicating that its share price is 621% more volatile than the broader market. Comparatively, Mainz Biomed has a beta of 0.31, indicating that its share price is 69% less volatile than the broader market.

Mainz Biomed has lower revenue, but higher earnings than ZenaTech. ZenaTech is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ZenaTech	$9.24M	4.09	-$32.36M	-$1.42	N/A
Mainz Biomed	$659.94K	20.87	-$21.65M	-$65.60	N/A

In the previous week, ZenaTech had 7 more articles in the media than Mainz Biomed. MarketBeat recorded 7 mentions for ZenaTech and 0 mentions for Mainz Biomed. ZenaTech's average media sentiment score of 0.31 beat Mainz Biomed's score of 0.00 indicating that ZenaTech is being referred to more favorably in the media.

Company	Overall Sentiment
ZenaTech	Neutral
Mainz Biomed	Neutral

ZenaTech presently has a consensus price target of $4.50, indicating a potential upside of 167.86%. Given ZenaTech's stronger consensus rating and higher possible upside, equities research analysts plainly believe ZenaTech is more favorable than Mainz Biomed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ZenaTech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Mainz Biomed	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Summary

ZenaTech beats Mainz Biomed on 8 of the 13 factors compared between the two stocks.

How does Mainz Biomed compare to VirTra?

Mainz Biomed (NASDAQ:MYNZ) and VirTra (NASDAQ:VTSI) are both small-cap industrials companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, media sentiment, valuation, dividends, risk and profitability.

Mainz Biomed has a net margin of 0.00% compared to VirTra's net margin of -17.04%. Mainz Biomed's return on equity of 0.00% beat VirTra's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mainz Biomed	N/A	N/A	N/A
VirTra	-17.04%	-6.59%	-4.57%

VirTra has a consensus target price of $5.00, suggesting a potential upside of 61.81%. Given VirTra's stronger consensus rating and higher possible upside, analysts plainly believe VirTra is more favorable than Mainz Biomed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mainz Biomed	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
VirTra	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

VirTra has higher revenue and earnings than Mainz Biomed. VirTra is trading at a lower price-to-earnings ratio than Mainz Biomed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mainz Biomed	$659.94K	20.87	-$21.65M	-$65.60	N/A
VirTra	$22.40M	1.56	$260K	-$0.26	N/A

In the previous week, VirTra had 1 more articles in the media than Mainz Biomed. MarketBeat recorded 1 mentions for VirTra and 0 mentions for Mainz Biomed. VirTra's average media sentiment score of 1.00 beat Mainz Biomed's score of 0.00 indicating that VirTra is being referred to more favorably in the news media.

Company	Overall Sentiment
Mainz Biomed	Neutral
VirTra	Positive

Mainz Biomed has a beta of 0.31, indicating that its stock price is 69% less volatile than the broader market. Comparatively, VirTra has a beta of 0.71, indicating that its stock price is 29% less volatile than the broader market.

14.7% of VirTra shares are owned by institutional investors. 18.2% of Mainz Biomed shares are owned by insiders. Comparatively, 3.5% of VirTra shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

VirTra beats Mainz Biomed on 10 of the 16 factors compared between the two stocks.

Get Mainz Biomed News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MYNZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MYNZ vs. The Competition

Export

Metric	Mainz Biomed	Aerospace & Defense Industry	Industrials Sector	NASDAQ Exchange
Market Cap	$13.77M	$21.16B	$10.43B	$12.92B
Dividend Yield	N/A	1.67%	97.26%	8.90%
P/E Ratio	-0.02	38.25	26.27	25.42
Price / Sales	20.87	145.93	382.33	89.63
Price / Cash	N/A	27.33	24.10	52.28
Price / Book	0.58	6.07	4.62	6.17
Net Income	-$21.65M	$562.41M	$609.95M	$349.50M
7 Day Performance	7.04%	-2.25%	-0.76%	-0.15%
1 Month Performance	1.33%	-6.72%	-1.49%	1.02%
1 Year Performance	-6.75%	9.73%	9.49%	14.50%

Mainz Biomed Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MYNZ Mainz Biomed	N/A	$1.52 -5.0%	N/A	-9.5%	$13.77M	$659.94K	N/A	30	High Trading Volume
TPCS Techprecision	0.7533 of 5 stars	$5.40 -2.4%	N/A	+8.4%	$54.54M	$31.64M	N/A	160	Gap Down
XTIA XTI Aerospace	0.5284 of 5 stars	$1.15 -14.8%	N/A	-47.0%	$44.25M	$22.49M	N/A	12	News Coverage
SYPR Sypris Solutions	1.0833 of 5 stars	$1.84 +1.1%	N/A	-16.9%	$42.38M	$119.89M	N/A	680	Positive News
ZENA ZenaTech	3.0008 of 5 stars	$1.68 -4.3%	$4.50 +168.7%	-64.4%	$37.69M	$9.24M	N/A	11	News Coverage Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MYNZ) was last updated on 9/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Mainz Biomed (MYNZ) Competitors

MYNZ vs. TPCS, XTIA, SYPR, ZENA, and VTSI

How does Mainz Biomed compare to Techprecision?

Summary

How does Mainz Biomed compare to XTI Aerospace?

Summary

How does Mainz Biomed compare to Sypris Solutions?

Summary

How does Mainz Biomed compare to ZenaTech?

Summary

How does Mainz Biomed compare to VirTra?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MYNZ vs. The Competition

Mainz Biomed Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Mainz Biomed (MYNZ) Competitors

MYNZ vs. TPCS, XTIA, SYPR, ZENA, and VTSI

How does Mainz Biomed compare to Techprecision?

Do institutionals and insiders believe in MYNZ or TPCS?

Does the media refer more to MYNZ or TPCS?

Which has more volatility and risk, MYNZ or TPCS?

Which has better valuation & earnings, MYNZ or TPCS?

Is MYNZ or TPCS more profitable?

Do analysts rate MYNZ or TPCS?

Summary

How does Mainz Biomed compare to XTI Aerospace?

Do insiders & institutionals hold more shares of XTIA or MYNZ?

Does the media refer more to XTIA or MYNZ?

Is XTIA or MYNZ more profitable?

Which has preferable valuation & earnings, XTIA or MYNZ?

Do analysts rate XTIA or MYNZ?

Which has more volatility & risk, XTIA or MYNZ?

Summary

How does Mainz Biomed compare to Sypris Solutions?

Is SYPR or MYNZ more profitable?

Do insiders and institutionals believe in SYPR or MYNZ?

Which has more volatility and risk, SYPR or MYNZ?

Which has stronger earnings & valuation, SYPR or MYNZ?

Does the media refer more to SYPR or MYNZ?

Do analysts recommend SYPR or MYNZ?

Summary

How does Mainz Biomed compare to ZenaTech?

Is ZENA or MYNZ more profitable?

Which has more risk & volatility, ZENA or MYNZ?

Which has better earnings and valuation, ZENA or MYNZ?

Does the media prefer ZENA or MYNZ?

Do analysts recommend ZENA or MYNZ?

Summary

How does Mainz Biomed compare to VirTra?

Is MYNZ or VTSI more profitable?

Do analysts recommend MYNZ or VTSI?

Which has preferable earnings and valuation, MYNZ or VTSI?

Does the media refer more to MYNZ or VTSI?

Which has more risk & volatility, MYNZ or VTSI?

Do insiders & institutionals have more ownership in MYNZ or VTSI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MYNZ vs. The Competition

Mainz Biomed Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools